The SynCon FAP DNA vaccine synergized with other tumor-antigen-specific DNA vaccines showed a stronger anti-tumor activity than monotherapy, and the SynCon FAP DNA vaccine itself exerted remarkable antitumor effect in the TC-1, Brpkp110, and TSA tumor models [216]. This evidence concerns the gene FAP and neoplasm.